Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Valdecoxib: a review.

Mary L Chavez1, Carrie J DeKorte

  • 1Pharmacy Practice Department, College of Pharmacy, Midwestern University-Glendale, Glendale, Arizona 85308, USA. mchave@arizona.midwestern.edu

Clinical Therapeutics
|July 11, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of Stress and Quality of Life in Non-native and Native English-speaking Pharmacy Students.

American journal of pharmaceutical education·2021
Same author

Identifying opportunities for PharmD curricular reform by surveying oncology pharmacists about career preparedness and exposure.

Currents in pharmacy teaching & learning·2019
Same author

White Paper on Natural Products.

Pharmacotherapy·2016
Same author

United States pharmacopeia safety evaluation of spirulina.

Critical reviews in food science and nutrition·2011
Same author

Assessing safety of herbal products for menopausal complaints: an international perspective.

Maturitas·2010
Same author

The state of dietary supplement adverse event reporting in the United States.

Pharmacoepidemiology and drug safety·2008
Same journal

Reimagining Representation Across the Clinical Research Ecosystem: Part II of a Specialty Update on Advancing Diversity, Racial Equity, and Inclusion in Clinical Research.

Clinical therapeutics·2026
Same journal

Combined Effects of Nicorandil and Enhanced External Counterpulsation on Coronary Microcirculation and Exercise Capacity in Patients With Coronary Slow Flow Phenomenon: A Randomized, Controlled, 3-Arm Trial.

Clinical therapeutics·2026
Same journal

Phase 1 Study Evaluating Gefurulimab Pharmacokinetics and Safety Following Delivery Via Autoinjector or Prefilled Syringe With Needle Safety Device in Healthy Adults.

Clinical therapeutics·2026
Same journal

Evaluating Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Associated With Newer Antiseizure Medications Using FAERS and JADER Combined With Bioinformatics Exploration.

Clinical therapeutics·2026
Same journal

Diversity: A Medical Research Imperative.

Clinical therapeutics·2026
Same journal

LOARGYS (pegzilarginase-nbln).

Clinical therapeutics·2026
See all related articles

Valdecoxib, a COX-2 selective inhibitor, effectively treats arthritis and pain with fewer gastrointestinal issues than traditional NSAIDs. It is recommended for patients at risk of NSAID-induced gastrointestinal problems.

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Rheumatology

Background:

  • Traditional nonsteroidal anti-inflammatory drugs (NSAIDs) non-selectively inhibit cyclooxygenase-1 (COX-1) and COX-2, leading to therapeutic effects but also gastric and renal side effects.
  • Sparing COX-1 is believed to be beneficial for gastric safety.
  • Valdecoxib is a novel COX-2 selective inhibitor.

Purpose of the Study:

  • To review the clinical pharmacology, pharmacokinetics, adverse effects, drug interactions, contraindications, and warnings of valdecoxib.
  • To summarize clinical trial results on valdecoxib's efficacy and tolerability.

Main Methods:

  • Literature search of PubMed, MEDLINE, and International Pharmaceutical Abstracts (1966-2002).
  • Included search terms: valdecoxib, Bextra, COX-2-selective inhibitors, coxibs, selective cyclooxygenase inhibitors.

Related Experiment Videos

  • Reviewed reference lists and manufacturer product information.

    • Main Results:

    • Valdecoxib demonstrated significant efficacy over placebo in treating rheumatoid arthritis, osteoarthritis, primary dysmenorrhea, and postoperative pain.
    • Efficacy was comparable to naproxen for rheumatoid arthritis and osteoarthritis.
    • Valdecoxib showed lower rates of gastroduodenal ulcer formation compared to ibuprofen, naproxen, and diclofenac, and did not inhibit platelet function.

    Conclusions:

    • Valdecoxib is effective for osteoarthritis, rheumatoid arthritis, and moderate to severe pain associated with primary dysmenorrhea.
    • Valdecoxib appears to cause less gastrointestinal toxicity than nonselective NSAIDs.
    • Use of valdecoxib should be considered for patients at risk for NSAID-induced gastrointestinal issues.